Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by premium54on Jan 19, 2017 7:58am

81 Views

Post# 25726751

RE:RE:RE:Garbage stock

i dont have to drive down anything its already down and its gonna get worse.

Folks, you have invested in a brand new company. You have to expect that until it gets more press the stock will be under pressure. If you invested in this to day trade it then you picked the wrong stock.

If you invested in this because you did you DD, you checked out the principals and you were smart enough to realize that if this drug works this stock will be north of
$20.00 then congratulations, I think you picked a winner.

Give this baby time, the drug is amazing, we just have to finish trials and if everthing goes well you will be well rewarded.

Aprhia thought enough of this company to give them 1mm and Mr. Neufeld is one smart cookie.

Bullboard Posts

Debt-free cannabis company set for next stage of growth